Greg Licholai

Chief Medical & Innovation Officer, ICON plc

Dr. Greg Licholai is Chief Medical and Innovation Officer at ICON plc, a global healthcare intelligence and clinical research organization. He is on the faculty at Yale School of Management and is Co-Director of the Center for Digital Health. Previously, he was President of rare disease at Moderna Therapeutics, President and Chief Medical Officer at Castle Creek Pharmaceuticals, and partner at McKinsey & Co. where he ran the healthcare data service line. He was also a senior executive at Proteostasis, Amicus Therapeutics and Medtronic Neurological as well as venture investor for Domain Associates. He was co-founder of Immunome Therapeutics.

Greg has degrees from Harvard Business School, Yale School of Medicine, Columbia University and Boston College. He trained at the Brigham and Women’s, Children’s, and Massachusetts General Hospitals. He serves on multiple company and non-profit boards including advisor to the Clinical Trials Transformation Initiative (CTTI), a public private partnership co-founded by Duke University and the Food and Drug Administration (FDA). He writes about innovation in healthcare for Forbes.

Greg Licholai is a part of the ICON. Learn More
Scroll to Top